Ethan Aw

APAC IPOs & Placements

Aequitas Research

IPOs and Placements coverage across Asia Pacific

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/fangzhou-group" target="_blank" data-smartkarma-citation="entities:36560:1" rel="noopener">Fangzhou Group (FANGZHOU HK)</a> is looking to raise about US$300m in its upcoming HK IPO. The deal will be run by Citibank, UBS and ABC International. </li>
<li>Fangzhou Group is an online chronic disease management platform in China, considered the largest in terms of average MAU in 2021, according to CIC.</li>
<li>It focuses on common and chronic diseases such as hypertension, cardiovascular and respiratory chronic diseases, providing tailored medical care and precision medicine covering the full disease cycle for patients.</li>
</ul>

Fangzhou Group - FANGZHOU HK